Trials / Recruiting
RecruitingNCT05305911
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition Improves Left Ventricular Function and Reduces Adverse Left-Ventricular Remodeling in High-Risk Patients with Microvascular Obstruction (MVO) Following ST-elevation Myocardial Infarction (STEMI).
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 81 (estimated)
- Sponsor
- Minneapolis Heart Institute Foundation · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGLT-2 inhibitors | SGLT2 inhibitor once daily for six months |
| DRUG | Placebo | Placebo once daily for six months |
Timeline
- Start date
- 2022-08-03
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
- First posted
- 2022-03-31
- Last updated
- 2024-10-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05305911. Inclusion in this directory is not an endorsement.